Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2018
At a glance
- Drugs Dasatinib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 26 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 06 Dec 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.